Glioblastoma Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Glioblastoma Market Summary
The Glioblastoma Treatment Market size in the 7MM was estimated at USD 799 million in 2021 and is projected to grow over the forecast period from 2024 to 2034.

Discover which therapies are expected to grab the Glioblastoma Market Share @ Glioblastoma Market Forecast - https://www.delveinsight.com/report-store/glioblastoma-market?utm_source=openpr&utm_medium=pr&utm_campaign=anigam

Glioblastoma Market Size and Forecast
The United States glioblastoma market is projected to grow at a CAGR of 13.1%, while the EU4 (Germany, France, Italy, Spain) and the UK are expected to expand at 13.5% CAGR. In Japan, the market will increase at a slower yet steady 10.4% CAGR during the forecast period. Currently, Temozolomide (Temodar) and Bevacizumab (Avastin) are the only approved therapies, but limited efficacy highlights the urgent need for innovative treatments. The upcoming launch of Bevacizumab biosimilars may ease the cost burden, while advances in molecular and genetic research are driving the development of more personalized therapies. Despite a robust pipeline, many candidates fail in late-phase trials, leaving a significant market opportunity for vaccines, immunotherapies, and oncolytic virus-based treatments to reshape the glioblastoma treatment landscape.

DelveInsight's report, "Glioblastoma Market Insights, Epidemiology, and Market Forecast - 2034" provides a comprehensive overview of Glioblastoma, including historical and projected epidemiology as well as therapeutic market trends across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. The report presents detailed insights into revenue patterns, disease prevalence, and the treatment landscape, while also analyzing the market size and growth potential. It further explores the pipeline of emerging therapies, their clinical progress, and the impact of ongoing and upcoming trials expected to shape future treatment strategies. This study serves as a valuable resource for understanding market dynamics and the evolving therapeutic opportunities in Glioblastoma.
Glioblastoma Overview
Glioblastoma, an aggressive brain tumor, remains challenging to treat due to its rapid growth and resistance to conventional therapies. Standard treatment involves surgical resection, followed by radiotherapy and temozolomide chemotherapy. Emerging therapies, including targeted drugs, immunotherapies, and tumor-treating fields, are showing promise in clinical trials. Despite advancements, prognosis remains poor, highlighting the urgent need for novel, effective treatments to improve survival and quality of life for patients.

Stay ahead in oncology R&D with our latest pipeline review glioblastoma treatment market overview, covering immunotherapies and targeted agents, visit @ Glioblastoma Treatment Market Landscape - https://www.delveinsight.com/sample-request/glioblastoma-market?utm_source=openpr&utm_medium=pr&utm_campaign=anigam

Recent Development in Glioblastoma Clinical Research
• In May 2025, Shuttle Pharmaceuticals (Nasdaq: SHPH) announced that it had nearly reached 50% enrollment in its Phase 2 trial of Ropidoxuridine for glioblastoma. The drug has been well tolerated, with low toxicity (grade ≤2), and 84% of enrolled patients have completed all seven treatment cycles.
• In December 2024, Kazia Therapeutics was informed by the FDA that accelerated approval for its brain cancer drug, paxalisib, is unlikely. The FDA noted that the Phase II/III GBM-AGILE study's overall survival data, showing a 3.8-month improvement in glioblastoma patients, did not meet the criteria for accelerated approval.
• On October 15, 2024, the FDA granted Fast Track designation to LP-184, a small-molecule alkylating agent developed by Lantern Pharma for glioblastoma treatment. LP-184 induces tumor cell death through DNA damage and is currently being evaluated in a Phase 1a trial for safety and tolerability in patients with various solid tumors, including GBM. The Fast Track designation is intended to expedite the development and review of LP-184, given the limited treatment options for aggressive brain cancers such as GBM.

Key Glioblastoma Companies In The Market Landscape:
The key players in the Glioblastoma market who are in different phases of developing Glioblastoma Therapies are - Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, and Many Others.

Download the report to understand which factors are driving Glioblastoma Epidemiology trends @ Glioblastoma Patient Population and Epidemiological Insights - https://www.delveinsight.com/report-store/glioblastoma-market?utm_source=openpr&utm_medium=pr&utm_campaign=anigam

Glioblastoma Epidemiology Insights
Glioblastoma multiforme (GBM) is the most common and aggressive form of primary malignant brain tumor in adults, accounting for approximately 45-50% of all primary brain cancers. Its annual incidence is estimated at 3-5 cases per 100,000 individuals globally, with slightly higher rates observed in developed countries. The disease predominantly affects individuals aged 65-75 years and exhibits a slight male predominance. Despite aggressive treatment, the median survival remains less than 15 months.
Key Highlights:
• The epidemiology segment provides Glioblastoma prevalence data across the United States, EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• The total diagnosed incident population of Glioblastoma in the 7MM was 32,546 cases in 2021, with numbers projected to increase over the forecast period.
• In the United States, the gender-specific incidence showed a higher number of cases in males, with 7,705 cases recorded in 2021, compared to females.
• Within the EU-4 and the UK, Germany reported the highest number of Glioblastoma cases in 2021, followed by France, while Spain had the lowest.
• In Japan, Glioblastoma incidence is categorized into two types, with Primary Glioblastoma/IDH-wild Type accounting for the majority at 2,541 cases in 2021, and these numbers are expected to rise during the forecast period.

Glioblastoma Drugs and Therapies
Advancements in treatment strategies are focusing on personalized medicine, immunotherapy, and gene therapy. Notably, gene therapy approaches, such as VBL Therapeutics' VB-111 (Ofranergene obadenovec), are under clinical evaluation for recurrent GBM. Additionally, CAR T-cell therapies are being explored for their potential in treating GBM, with early-stage trials showing promising results. These innovative therapies aim to improve patient outcomes and address the challenges posed by the aggressive nature of GBM.

Learn more about the FDA-approved drugs for Glioblastoma @ Drugs for Glioblastoma Treatment - https://www.delveinsight.com/sample-request/glioblastoma-market?utm_source=openpr&utm_medium=pr&utm_campaign=anigam

Glioblastoma Marketed Drugs
• Avastin: Genentech
Avastin (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody that acts as an angiogenesis inhibitor by blocking vascular endothelial growth factor (VEGF). Bevacizumab binds to VEGF receptors VEGFR-1 and VEGFR-2 on endothelial cells. In December 2017, the US FDA granted full approval of Avastin for the treatment of adults with recurrent glioblastoma that has progressed following prior therapy.
• Temodar/Temodal: Merck
Temodar/Temodal contains temozolomide, an imidazotetrazine derivative of the alkylating agent dacarbazine. It is used for treating several brain cancers, including as a second-line treatment for astrocytoma and as a first-line treatment for glioblastoma. Temozolomide exerts its therapeutic effect through DNA alkylation/methylation. In July 2006, the Japan Ministry of Health, Labor and Welfare (MHLW) approved Temodal capsules for malignant glioma treatment.

Emerging Glioblastoma Drugs
• Ofranergene obadenovec (VB-111): VBL Therapeutics
Ofranergene obadenovec (VB-111) is a first-in-class targeted anticancer gene therapy in development for solid tumors including glioblastoma. It is a non-replicating adenovirus 5 (Ad-5, E1-deleted) carrying a proapoptotic human Fas-chimera transgene that targets angiogenic blood vessels, leading to vascular disruption. The drug has received Orphan Drug Designation from the US FDA and EMA and Fast Track Designation by the US FDA. VB-111 has completed Phase III trials in patients with recurrent glioblastoma. In November 2017, VBL Therapeutics signed an exclusive license agreement with NanoCarrier for development and commercialization in Japan.
• Trans Sodium Crocetinate: Diffusion Pharmaceuticals
Trans Sodium Crocetinate (TSC) is a first-in-class small molecule that reoxygenates hypoxic tissue, enhancing the efficacy of radiation and chemotherapy. It is being investigated as a treatment for glioblastoma and addresses unmet clinical needs across multiple markets.
• Selinexor (KPT-330): Karyopharm Therapeutics
Selinexor (KPT-330) is an oral Selective Inhibitor of Nuclear Export (SINE) compound that inhibits XPO1, leading to nuclear accumulation of tumor suppressor proteins and selective induction of apoptosis in cancer cells. Selinexor is approved as Xpovio for relapsed/refractory multiple myeloma in combination with dexamethasone. Its Phase II (KING) study in glioblastoma was terminated due to sponsor decision.
• VBI-1901: VBI Vaccines
VBI-1901 is a cancer vaccine designed to treat glioblastoma and medulloblastoma by targeting cytomegalovirus (CMV) within tumor cells, enhancing immune response. It is in Phase I/II development for recurrent glioblastoma, with plans for a randomized, controlled study. In June 2021, the FDA granted Fast Track designation for VBI-1901.
• ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
ITI-1000 is an autologous dendritic cell vaccine loaded with mRNA encoding CMV pp65 fused with shLAMP, designed to stimulate an antitumor immune response. It is being evaluated in the Phase II ATTAC-II trial for glioblastoma and related malignancies, funded by the National Cancer Institute.

Discover more about Glioblastoma Drugs in development @ Glioblastoma Clinical Trials and FDA Approvals - https://www.delveinsight.com/sample-request/glioblastoma-market?utm_source=openpr&utm_medium=pr&utm_campaign=anigam

Glioblastoma Market Drivers
• Launch of Novel Therapies: The introduction of gene therapies, vaccines, and oncolytic virus therapies such as Ofranergene obadenovec (VB-111), VBI-1901, and ITI-1000 is expected to boost market growth by addressing unmet treatment needs.
• Rising Incidence and Diagnosis: Increasing cases of glioblastoma in adults globally, combined with advances in imaging and molecular diagnostics, are leading to higher detection rates and treatment uptake.
• Strong Pipeline Development: Late- and mid-stage pipeline candidates like Paxalisib (GDC-0084), LAM561, DNX-2401, and VAL-083 are expected to diversify treatment options, potentially improving survival outcomes.
• Regulatory Incentives and Fast-Track Approvals: Designations such as Fast Track, Orphan Drug, and FDA accelerated approvals facilitate quicker market entry for innovative therapies, enhancing growth prospects.
• Expanding Market in Key Geographies: The United States, EU4 countries, the UK, and Japan represent major revenue-generating markets, with projected CAGRs of 13.1%, 13.5%, and 10.4% respectively over 2020-2034.
• Reduction in Cost Burden via Biosimilars: Introduction of Bevacizumab biosimilars is expected to improve accessibility and reduce treatment costs, supporting market expansion.

Glioblastoma Market Barriers
• Limited Curative Options: Despite approved therapies like Temozolomide (Temodar) and Bevacizumab (Avastin), glioblastoma remains largely incurable, limiting long-term growth opportunities.
• High Failure Rate in Clinical Trials: Many emerging therapies fail in late-phase clinical trials, which could delay market expansion and reduce investor confidence.
• Complexity of Treatment Regimens: Treatment often requires a combination of surgery, chemotherapy, radiation, and adjuvant therapies, making therapy selection and patient adherence challenging.
• High Cost of Novel Therapies: Advanced therapies, including gene and vaccine-based treatments, have significant cost and reimbursement challenges, restricting patient access.
• Blood-Brain Barrier Limitations: Delivering effective concentrations of therapeutic agents across the blood-brain barrier (BBB) remains a major obstacle in glioblastoma management.
• Heterogeneity of Tumor Response: Glioblastoma cells vary in sensitivity to treatments, leading to variable patient outcomes and complicating the development of universally effective therapies.

Glioblastoma Market Outlook
Glioblastoma remains one of the most challenging brain cancers to treat, requiring a multimodal approach that combines surgery, chemotherapy, radiation, and emerging therapies. Surgery aims for a "maximum safe resection," followed by adjuvant treatments to control tumor regrowth. The pipeline is advancing with innovative candidates such as VB-111 (VBL Therapeutics), VBI-1901 (VBI Vaccines), ITI-1000 (Immunomic Therapeutics), DNX-2401 (DNAtrix), and Paxalisib (Kazia Therapeutics), alongside other late- and mid-stage drugs expected to reshape the market.
In 2021, the Glioblastoma Treatment Market Size in the 7MM was USD 799 million, led by the US, followed by Germany in Europe, and Japan contributing USD 58 million. The market is projected to grow significantly, with the US showing a CAGR of 13.1%, the EU4+UK at 13.5%, and Japan at 10.4% between 2020-2034.
Glioblastoma Market Insights:
• According to estimates, the United States accounted for the highest Glioblastoma Treatment Market size in 2021.
• Within the EU-4 (Germany, France, Italy, Spain) and the UK, Germany held the largest revenue share in 2021, while Spain recorded the lowest market share.
• The Glioblastoma Treatment Market size in Japan was USD 58 million in 2021 and is projected to increase over the forecast period from 2024 to 2034.
The GBM treatment landscape is evolving with significant advancements in both therapeutic approaches and market dynamics. While the disease continues to present substantial clinical challenges, ongoing research and development efforts are paving the way for more effective treatments. The projected market growth reflects the increasing demand for innovative therapies and the global commitment to improving outcomes for GBM patients. Continued investment in research and collaboration among healthcare providers, researchers, and pharmaceutical companies will be crucial in transforming the prognosis for individuals affected by this formidable disease.

Scope of the Glioblastoma Market Research Report
• Coverage- 7MM
• Glioblastoma Companies- Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others.
• Glioblastoma Pipeline Therapies- ITI-1000 (pp65 DC Vaccine), VBI-1901, Selinexor (KPT-330), Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), Temodar/Temodal, Avastin, Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, and others.
• Glioblastoma Market Dynamics: Glioblastoma Market Drivers and Barriers
• Glioblastoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a global market research and consulting firm focused exclusively on life sciences. Through integration of epidemiology, pipeline intelligence, and market analytics, DelveInsight equips pharmaceutical, biotech, and investment stakeholders with actionable insights to navigate and capitalize on complex healthcare markets.

This release was published on openPR.